Introduction
There is a worldwide increase in the prevalence and incidence of diabetes, with new figures indicating a rise from 366 million people concerned in 2011 to 552 million by 2030. 1 The majority of these cases relate to type 2 diabetes mellitus (T2DM) and have to be seen in the context of increased obesity rates and a westernized, sedentary lifestyle. Type 2 diabetes patients face a dramatically increased risk of cardiovascular and cerebrovascular morbidity and mortality. It can be anticipated that the predicted rise in the prevalence of T2DM 2 and the trend to develop diabetes earlier in life will lead to a further increase in diabetes complications, including also diabetic visual impairment, renal failure, and amputations. 3 This review will give an overview on basal insulin therapy for T2DM in daily life, taking into account recommendations by international guidelines, the use of titration algorithms, and future perspectives for patients and primary care physicians. A PubMed search was performed, and clinical studies/scientific articles were considered until June 1, 2012.
The latest ADA/EASD position statement on the management of hyperglycemia in T2DM 8 emphasizes a flexible patientcentered treatment approach: "Ultimately, it is patients who make the final decisions regarding their lifestyle choices and, to some degree, the pharmaceutical interventions they use; their implementation occurs in the context of the patients' real lives and relies on the consumption of resources (both public and private)." The importance of a partnership between the patient and the physician and the involvement of the patient in medical decisions in order to support adherence to therapy is highlighted in the statement.
After initial drug monotherapy, i.e., usually metformin, the ADA/EASD position statement on its two-drug combinations already mentions insulin, which ideally should be a basal insulin [neutral protamine Hagedorn (NPH) insulin, insulin glargine, insulin detemir], most commonly given in combination with one or two noninsulin agent(s). "Insulin is typically begun at a low dose (e.g. 0.1-0.2 U kg -1 day -1 ), although larger amounts (0.3-0.4 U kg -1 day -1 ) are reasonable in the more severely hyperglycemic." 8 Noteworthy, the authors state that most patients-on the condition that daily self-monitoring of blood glucose occurs during this phase-can be taught to up-titrate their own insulin dose based on several algorithms, 11, 12 each essentially involving the addition of a small dose increase, e.g., 1-2 U (for those patients already on higher doses, increments of 5-10 %), to the daily dose once or twice weekly if the fasting blood glucose (FBG) levels are above the pre-agreed target. 13 Dose adjustments should be more modest and less frequent as the target comes close (frequency of self-monitoring of FBG also to be reviewed), and down-titration is recommended in case of occurrence of any hypoglycemia. During self-titration, frequent contact with the physician may be necessary. Remarkably, the position statement points out that practitioners themselves, of course, could also titrate basal insulin but that this would involve more intensive contact with the patient than typically available in routine medical care. Basal insulin should primarily be titrated against the FBG-generally irrespective of the total dose-although the physician should be aware that prandial insulin might be needed if the daily dose exceeds 0.5 U/kg/day or already approaches 1 U/kg/day. Given the estimate of an increasing number of people with T2DM on the one hand and the limited availability of health care resources on the other hand, it is easy to conclude that there is an obvious mismatch between supply and demand. It already is and will continue to be unfeasible to treat all patients with T2DM in specialized diabetes clinics or diabetes outpatient centers. The the majority of patients are and continue to be treated in a primary care setting, i.e., by their general practitioner.
These primary care providers, however, are often reluctant and apprehensive about using insulin in patients with T2DM. 14, 15 Their concerns/fears are related to the following:
• Lack of confidence in patient's ability to manage insulin therapy,
• Fear of hypoglycemia,
• Presumed unwillingness and/or inability of the patient to inject insulin,
• Complexity of insulin therapy is considered too difficult to be managed in a busy primary care practice,
• Uncertainties regarding initial insulin dosing and titration due to vague prescribing information provided by manufacturers, and
• Difficult logistics of communicating with the patient during/after insulin initiation and titration.
These factors could lead to an undue delay in making the necessary transition from oral agents to insulin. 14 Study data show that mean HbA1c levels are ≥9.0% (one-third >10.0%) and mean diabetes duration is 9.3 years prior to first insulinization with basal insulin in patients with T2DM in a real-world setting in Asia. 16 Data from other countries show similar figures. 17 This frequently observed delay in initiating necessary insulin treatment often leads to prolonged hyperglycemia and increases the risk of diabetes complications. 18 In another investigation 19 on diabetes knowledge carried out among internal medicine residents, family practice residents, surgery residents, and registered nurses, a 21-question survey revealed similar, but insufficient, levels of knowledge in these groups. Surgery residents had a more pronounced deficit of diabetes knowledge, whereas additional previous diabetes training among nurses was associated with greater diabetes knowledge.
Patients also have several barriers to insulin initiation. These include
• Lack of self-confidence to manage insulin therapy, 20 • Multifactorial psychological resistance to insulin therapy, 21 • Fear of hypoglycemia, 22 • Weight gain, 22 • Need for frequent blood glucose monitoring, 23 • Pain associated with needle use, 22 and
• Negative self-perceptions regarding insulin use (insulin, e.g., is regarded as sign of failure 24 or is considered to be responsible for a serious decline in health or for the onset of complications 22 and is sometimes also considered as punishment, and such psychological problems might negatively affect self-care 24 ).
Taking the aforementioned issues into account, it is not surprising that insulin initiation occurs only in a minority (approximately 5%) of patients per year from diagnosis or first prescription of oral antidiabetic (OAD) agents, then increases to 10% per year following failure of combination OAD treatment. 25 Nevertheless, insulin initiation with basal insulin including insulin analog in patients with T2DM can be managed successfully in both primary and secondary care, as shown in a 3-month longitudinal observational study across 761 centers in France; 22 mean HbA1c and FBG values decreased by 1.3% and 56 mg/dl from baseline, and rates of hypoglycemia were low compared with NPH insulin. The first basal insulin evaluation (or FINE) Asia study 16 also demonstrated effective and safe insulin initiation in 2679 patients from 11 Asian countries in a real-world setting.
A number of reviews and meta-analyses or pooled analyses deal with basal insulin therapy, including insulin initiation and titration algorithms for T2DM. 15, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] One conclusion is that once-daily basal insulin added to oral medication is an ideal start. 30, 36 A pooled analysis of 11 prospective randomized clinical trials involving 2171 adults with uncontrolled T2DM 30 investigated early initiation of insulin glargine-following a specific titration algorithm-added to metformin with or without sulfonylurea. Largest 24-week HbA1c reductions were observed for patients on 0 or 1 OAD or on metformin monotherapy at baseline; 68.1% of patients on metformin monotherapy + insulin glargine achieved an HbA1c ≤7.0%. Weight gain was also lowest when basal insulin was added to metformin, as were hypoglycemic events. Another previous systematic review and meta-analysis 33 found greater HbA1c reductions in insulin-naïve patients treated with biphasic or prandial insulin compared with basal insulin, but at the expense of higher FBG, more hypoglycemic events, and greater weight gain. A later review 25 stresses the urgent need of more simple, clear, consistent, and sustainable treatment regimens and guidelines. The authors also emphasize that enforced intensification of unrealistic complex treatment regimens and glycemic targets may theoretically worsen the psychological wellbeing of some patients.
In addition, numerous studies have been published on basal insulin therapy in patients with T2DM and on basal insulin regimen in combination with OADs or short-acting insulins with specific titration algorithms.
11-13,37-55 Table 1 provides an overview of these key studies and their intervention details. In the three-year 4-T study, 44 708 subjects with T2DM and poor glycemic control on metformin and sulfonylurea were randomly assigned to get basal insulin detemir or biphasic insulin aspart or prandial insulin aspart. The basal insulin regimen, which was equivalent to the other treatments after the first year in patients with HbA1c levels of ≤8.5%, was superior to both prandial and biphasic insulin after 3 years with regard to the rate of hypoglycemic events and weight gain. Thus, the three-year 4-T trial also supports the initiation of basal insulin. This is supported by the concept that fasting hyperglycemia has a greater impact on HbA1c levels than has postprandial hyperglycemia, which was demonstrated earlier by Monnier and coauthors; 56 the relative contribution of fasting hyperglycemia to HbA1c levels increased gradually as diabetes proceeded, whereas that of postprandial glucose excursions was prevailing in fairly well-controlled patients. Therefore, this also emphasizes the need to focus on FBG during insulin therapy-especially basal insulin therapy-in T2DM.
The 22 clinical trials cited investigated basal insulin therapy together with the use of different treatment algorithms, either directed by the clinic/physician-with or without central enforcement-or by the patients themselves. All trials have consistently shown substantial improvements in glycemic control as indicated by reductions in HbA1c values and FBG together with a low number of hypoglycemic episodes.
The following important aspects however, should be noted when evaluating basal insulin titration algorithms (see Appendix 1 for details including studies):
• Starting insulin dose:
The majority of the studies used 10 U per day.
• Fasting Blood Glucose target:
The majority of trials set an FBG target of 100 mg/dl.
• Insulin titration steps:
Most algorithms stated steps of 2 U.
• Insulin titration frequency:
This primarily was twice per week or every 3 days.
• The driver of the titration (physician-versus patient-driven insulin titration):
Patients were found to be as good as physicians in titration.
• Efficacy of the titration algorithm in terms of HbA1c and FBG:
All studies found improvements in HbA1c and FBG.
• Safety of the titration algorithm in terms of hypoglycemic episodes: Hypoglycemia rates were low in all key studies.
• Concomitant antidiabetic medication(s):
Metformin was continued in all studies.
• Other factors with potential impact on basal insulin titration: (a) Day-to-day blood glucose variability, (b) Insulin dose, and (c) Practicability and complexity of titration algorithms.
What Are the Future Perspectives?
Taking all aspects together, there appears to be an apparent gap between international guideline recommendations, the results of clinical trials, and real-life clinical practice 25 as far as basal insulin initiation and treatment optimization in T2DM-including titration algorithms-is concerned. Putting this in the context of exploding diabetes prevalence rates in the near future and the necessity to treat patients at a general practitioner's level, strategies and tools are urgently needed to help both patients and primary care physicians efficiently initiate and continue basal insulin therapy.
One pilot trial investigated the translation of comparative effectiveness into practice by developing and using a decision aid tool, which proved to be acceptable to patients and providers and effective for knowledge translation. 57 Another study evaluated the effectiveness of a computerized order template for basal-bolus insulin among internal medicine resident teams in acute general medical floors. Use of the template was associated with improved mean blood glucose levels without increasing hypoglycemia in patients with T2DM. 58 Safety and efficacy of weekly dose adjustments has been demonstrated in a feasibility study in type 1 and T2DM. 59 Participation of general practitioners in quality assurance programs (repeated audit cycles) led to improved diabetes management in an investigation in Western Australia. 60 As a result of another survey, 19 repeated training provided to general practitioners and diabetes nurses might also lead to improvements in diabetes knowledge and therapy.
Another option could consist of automated insulin dose calculators as supportive tools for both patients with T2DM starting basal insulin therapy and the primary care physician who is treating these patients. Such calculators already exist for bolus insulin (primarily for insulin pumps or intensive care units), and several studies on such devices or programs have been published. [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] It is imaginable that the availability of basal insulin dose calculators that incorporate basal insulin titration algorithms-under the condition that the previously mentioned issues are taken into accountassists patients and physicians in real life and leads to substantial improvements of diabetes control. This improvement of diabetes control should be proven in controlled trials.
One major and still unmet need in diabetes therapy is therefore the translation of simple and effective treatment strategies to daily practice and the empowerment of patients who need insulin to self-manage this therapy. The first step to achieve this aim would be to strengthen the self-confidence of patients to master the initiation of insulin treatment, to address their fears, and to provide practical and effective algorithms for initiation and subsequent dose adaptation of insulin administration.
Summary and Conclusion
Type 2 diabetes has become a major health burden with further increasing prevalence rates. The majority of patients already is and will be treated by primary care physicians. The current joint position statement of the ADA and the EASD points out the importance of basal insulin therapy in T2DM. Numerous clinical trials have shown that basal insulin can be initiated successfully using basal insulin titration algorithms. Such algorithms can even be handled (1) 3.9-5.0, successfully by the patients themselves, as seen by substantial improvements in metabolic control, i.e., reduced HbA1c levels together with low rates of hypoglycemia. Practical tools, however, are needed to support patients and their physicians and to facilitate everyday life and thereby to prevent undue and harmful delay in initiating necessary insulin treatment. A successful option in this context could be a therapeutic strategy that takes into account patientrelevant aspects of care and facilitates the initiation and dose adaptation of insulin treatment using an automated basal insulin dose calculator that is simple to use and effective in achieving the agreed therapeutic targets. The clinical outcome of this approach should be proven in controlled trials.
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Sabine monotherapy. 30 A meta-analysis 57 pointed out reductions of approximately 50% of risk for nocturnal hypoglycemia with use of insulin glargine instead of NPH insulin. In contrast to the well-described and standardized titration schedules for the up-dosing of insulin to reach target, insulin dose reduction to counterbalance hypoglycemic events is much less standardized. The definition of hypoglycemia differs between the studies summarized in Table 1 with regard to blood glucose values and/or symptoms as well as the proposed dose adjustments. Taking into consideration that hypoglycemia is of relevant concern in health care professionals as well as patients, a dose reduction of 2-4 U as proposed in several studies 43, 47, 51, 54 or even 10% 39 may be most useful to avoid recurrence of hypoglycemic events.
Concomitant Antidiabetic Medication(s)
Oral antidiabetic medication consisted mainly of metformin monotherapy, which was continued in all the studies, or metformin + sulfonylureas. Sulfonylureas could be continued, if applicable, with the exception of one study. 39 In the three-year 4-T study, sulfonylureas were also discontinued at the start of the second year. 44 It remains unclear whether sulfonylureas can be safely continued when introducing basal insulin. Another study discontinued thiazolidinediones. 46 One trial allowed dose reduction or discontinuation of OADs. 40 One trial used sitagliptin or exenatide in addition to titrated insulin glargine + metformin ( Table 1) . 37 
Other Factors with Potential Impact on Basal Insulin Titration

Day-to-Day Blood Glucose Variability
A study investigating the day-to-day variability of FPG in 193 newly diagnosed patients with T2DM 74 exhibited FPG variations of ±15% on a daily basis. Subjects with higher FPG were more likely to experience larger changes in FPG values measured from day to day. Another investigation looked at the 8-week mean glucose in 204 subjects with T2DM treated with insulin; 75 the eight-week mean ± standard deviation glucose was 9.9 ± 2.2 mmol/liter, and the average overall coefficient of variation was 35.6% ± 7.7%. A higher variation was seen in older subjects and in those with longer duration of insulin therapy, greater consumption of sugars, and greater confidence in their self-care abilities. Lower variations were observed in obese subjects, subjects who were more compliant, and those receiving larger insulin doses. Multivariate analyses demonstrated that treatment duration, sugar consumption, medication compliance, and insulin doses were independently associated with glucose variation. Fasting variation was more influenced by medication compliance, whereas, before lunch, variation was more strongly influenced by body mass.
Bearing in mind these day-to-day variability factors, it seems appropriate not to titrate the insulin dose too often. Based on clinical experience, dose adjustments every three days as used in several studies could be considered as appropriate in this respect.
Insulin Dose
Longer-term trials have shown that the insulin dose over time keeps increasing, e.g., the insulin detemir dose increased from 0.66 to 0.77 U/kg or 17% from weeks 12 through 24. 35, 43 The increase may also be moderate as described by Schreiber and Haak, 72 where patients showed durable control with 20 U daily dose at 9 months and 22 U at 20 months. Therefore, a close eye should be kept on insulin dose development in the long run, and one should not miss the point to think of additional-prandial-insulin as soon as this is deemed to be appropriate, e.g., if the total dose reaches a level between 0.5 and 1.0 U/kg. 8 
Practicability and Complexity of Titration Algorithms
The key clinical studies cited used different kinds of basal insulin titration algorithms, from few to many steps, different step sizes (i.e., amount of insulin units to be increased or decreased), and also different titration frequencies. They also varied as to which person was responsible for the titration: clinic/physician ± central enforcement versus patient.
It is of great importance, however, that insulin titration is manageable for the patients in their daily life. Thus titration algorithms should be as simple as possible to support both primary care physicians and patients in optimizing basal insulin therapy. Increased standardization of titration schemes would benefit health care professionals and patients alike. The algorithms should also be in line with national and international diabetes guidelines that, in addition, need to be consistent in their recommendations.
